The Business Research Company

The Business Research Company's Organ Transplant Immunosuppressant Drugs Industry Report: Competitive Landscape and Future Prospects

LONDON, GREATER LONDON, UNITED KINGDOM, December 8, 2025 /EINPresswire.com/ -- "What Is The Projected Market Size & Growth Rate Of The Organ Transplant Immunosuppressant Drugs Market?
The market size for immunosuppressant drugs used in organ transplants has been on a consistent growth trajectory in the previous years. There is a projected increase from $5.35 billion in 2024 to about $5.47 billion in 2025, boasting a compound annual growth rate (CAGR) of 2.2%. This considerable growth during the historical period can be linked to factors such as an increase in transplant operations, enhancements in healthcare infrastructure, advancements in research and development, the worldwide aging population, and heightened awareness.

The market size of immunosuppressant drugs for organ transplants is anticipated to experience consistent expansion in the coming years. It is predicted to reach a value of ""$6.48 billion by 2029, with a compound annual growth rate (CAGR) of 4.3%. The projected growth during this forecasted period can be accredited to the emergence of novel therapies, an increased rate of organ failures, personalized treatment options, worldwide health campaigns, and cooperation at an international level. Significant trends expected during the forecast period encompass technological innovations, advancements in technology, strategies for containing costs, consolidating markets and forming partnerships, and a rise in organ transplants.

Download a free sample of the organ transplant immunosuppressant drugs market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10143&type=smp

What Is The Crucial Factor Driving The Global Organ Transplant Immunosuppressant Drugs Market?
The demand for organ transplantation is on the rise, which will subsequently propel the market for organ transplant immunosuppressant drugs. Organ transplantation is a surgical operation whereby a sick or injured organ is replaced with a healthy one from a donor within the human body. It's a lifesaving process that substitutes impaired or failed organs with healthy ones supplied by a donor. The usage of immunosuppressant drugs is vital to avoid the body rejecting the newly transplanted organs - a situation that could result in organ rejection. The accessibility and efficacy of these immunosuppressant drugs play a crucial role in the overall success of the organ transplantation process. For example, in 2023, approximately 16,335 individuals donated one or more organs posthumously, according to data from the Organ Procurement and Transplantation Network (OPTN), a public-private partnership located in the US. Signifying a 9.6% increase as compared to 2022, this was the first year where the number of deceased donors surpassed 15,000. As a result, the escalating need for organ transplantation is a major contributing factor to the growth of the organ transplant immunosuppressant drugs market.

Who Are The Emerging Players In The Organ Transplant Immunosuppressant Drugs Market?
Major players in the Organ Transplant Immunosuppressant Drugs include:
• Astellas Pharma Inc.
• F. Hoffmann-La Roche AG
• Novartis AG
• Accord Healthcare Limited
• GlaxoSmithKline PLC
• Pfizer Inc.
• Sanofi S.A.
• Alsachim a Shimadzu Group Company
• Neovii Pharmaceuticals AG
• Zydus Lifesciences Limited

What Are Some Emerging Trends In The Organ Transplant Immunosuppressant Drugs Market?
The trend of product innovation is gaining traction in the organ transplant immunosuppressant drugs market. Major firms in the organ transplant immunosuppressant drugs sector are focusing on crafting inventive solutions like combination therapy in order to maintain their market presence. The use of two or more immunosuppressant drugs in combination therapy is becoming increasingly prevalent as it delivers greater immunosuppression whilst minimizing side effect risk. For example, in March 2024, Johnson & Johnson, a pharmaceutical and biotechnology firm based in the US, obtained FDA approval for OPSYNVI. This single-tablet combination of tadalafil, a PDE5 inhibitor, and macitentan, an ERA, is designed for the long-term handling of PAH. Patients with PAH, whether they are treatment-naive or currently using an ERA, PDE5 inhibitor, or both, can be administered OPSYNVI. Patients consistently receiving doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets may be suitable for OPSYNVI prescription.

What Segments Are Covered In The Organ Transplant Immunosuppressant Drugs Market Report?
The organ transplant immunosuppressant drugs market covered in this report is segmented –

1) By Drug Class: Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, Others Drug Classes
2) By Transplant Type: Heart, Kidney, Liver, Lung, Pancreas, Other Transplant Types
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Calcineurin Inhibitors: Cyclosporine, Tacrolimus
2) By Antiproliferative Agents: Azathioprine, Mycophenolate Mofetil, Mycophenolic Acid
3) By MTOR Inhibitor: Sirolimus, Everolimus
4) By Steroids: Prednisone, Methylprednisolone
5) By Other Drug Classes: Costimulation Blockers, Sodium Channel Blockers, Antibody-Based Therapies

View the full organ transplant immunosuppressant drugs market report:
https://www.thebusinessresearchcompany.com/report/organ-transplant-immunosuppressant-drugs-global-market-report

Which Region Is Projected To Hold The Largest Market Share In The Global Organ Transplant Immunosuppressant Drugs Market?
In 2024, North America dominated the organ transplant immunosuppressant drugs market. The Asia-Pacific region is forecasted to experience the most rapid growth during the predicted period. The market report encompasses various regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Organ Transplant Immunosuppressant Drugs Market 2025, By The Business Research Company

Data Protection As A Service Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/data-protection-as-a-service-global-market-report

Cloud Security Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cloud-security-global-market-report

Application Security Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/application-security-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info

The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.